OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years — IVY Network, 18 States, September 8–November 30, 2022
Diya Surie, Jennifer DeCuir, Yuwei Zhu, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 5152, pp. 1625-1630
Open Access | Times Cited: 106
Diya Surie, Jennifer DeCuir, Yuwei Zhu, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 5152, pp. 1625-1630
Open Access | Times Cited: 106
Showing 1-25 of 106 citing articles:
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study
Ronen Arbel, Alon Peretz, Ruslan Sergienko, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 8, pp. 914-921
Open Access | Times Cited: 123
Ronen Arbel, Alon Peretz, Ruslan Sergienko, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 8, pp. 914-921
Open Access | Times Cited: 123
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022
Mark W. Tenforde, Zachary A. Weber, Karthik Natarajan, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 5152, pp. 1616-1624
Open Access | Times Cited: 90
Mark W. Tenforde, Zachary A. Weber, Karthik Natarajan, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 5152, pp. 1616-1624
Open Access | Times Cited: 90
Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods
Ruth Link‐Gelles, Matthew E. Levy, Karthik Natarajan, et al.
JAMA Network Open (2023) Vol. 6, Iss. 3, pp. e232598-e232598
Open Access | Times Cited: 67
Ruth Link‐Gelles, Matthew E. Levy, Karthik Natarajan, et al.
JAMA Network Open (2023) Vol. 6, Iss. 3, pp. e232598-e232598
Open Access | Times Cited: 67
COVID-19 Surveillance After Expiration of the Public Health Emergency Declaration ― United States, May 11, 2023
Benjamin J. Silk, Heather M. Scobie, William M. Duck, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 19, pp. 523-528
Open Access | Times Cited: 67
Benjamin J. Silk, Heather M. Scobie, William M. Duck, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 19, pp. 523-528
Open Access | Times Cited: 67
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, et al.
BMJ (2023), pp. e075286-e075286
Open Access | Times Cited: 65
Niklas Worm Andersson, Emilia Myrup Thiesson, Ulrike Baum, et al.
BMJ (2023), pp. e075286-e075286
Open Access | Times Cited: 65
COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022
Amelia G. Johnson, Lauren Linde, Akilah R. Ali, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 6, pp. 145-152
Open Access | Times Cited: 49
Amelia G. Johnson, Lauren Linde, Akilah R. Ali, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 72, Iss. 6, pp. 145-152
Open Access | Times Cited: 49
Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study
Freja Kirsebom, Nick Andrews, Julia Stowe, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 11, pp. 1235-1243
Open Access | Times Cited: 48
Freja Kirsebom, Nick Andrews, Julia Stowe, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 11, pp. 1235-1243
Open Access | Times Cited: 48
Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB–Containing Vaccines
Spyros Chalkias, Nichole McGhee, Jordan L. Whatley, et al.
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 2, pp. e279-e286
Open Access | Times Cited: 47
Spyros Chalkias, Nichole McGhee, Jordan L. Whatley, et al.
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 2, pp. e279-e286
Open Access | Times Cited: 47
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case–control study
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 12, pp. 1089-1100
Open Access | Times Cited: 46
Sara Y. Tartof, Jeff Slezak, Laura Puzniak, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 12, pp. 1089-1100
Open Access | Times Cited: 46
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022
Mark W. Tenforde, Zachary A. Weber, Karthik Natarajan, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 71, Iss. 12, pp. 1637-1646
Open Access | Times Cited: 44
Mark W. Tenforde, Zachary A. Weber, Karthik Natarajan, et al.
MMWR Morbidity and Mortality Weekly Report (2023) Vol. 71, Iss. 12, pp. 1637-1646
Open Access | Times Cited: 44
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
Spyros Chalkias, Jordan L. Whatley, Frank Eder, et al.
Nature Medicine (2023) Vol. 29, Iss. 9, pp. 2325-2333
Open Access | Times Cited: 44
Spyros Chalkias, Jordan L. Whatley, Frank Eder, et al.
Nature Medicine (2023) Vol. 29, Iss. 9, pp. 2325-2333
Open Access | Times Cited: 44
mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States
Hung Fu Tseng, Bradley K. Ackerson, Lina S. Sy, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 44
Hung Fu Tseng, Bradley K. Ackerson, Lina S. Sy, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 44
Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques
Katherine McMahan, Frank Wegmann, Malika Aïd, et al.
Nature (2023) Vol. 626, Iss. 7998, pp. 385-391
Open Access | Times Cited: 40
Katherine McMahan, Frank Wegmann, Malika Aïd, et al.
Nature (2023) Vol. 626, Iss. 7998, pp. 385-391
Open Access | Times Cited: 40
Why Some People Are Hesitant to Receive COVID-19 Boosters: A Systematic Review
Yam B. Limbu, Bruce A. Huhmann
Tropical Medicine and Infectious Disease (2023) Vol. 8, Iss. 3, pp. 159-159
Open Access | Times Cited: 39
Yam B. Limbu, Bruce A. Huhmann
Tropical Medicine and Infectious Disease (2023) Vol. 8, Iss. 3, pp. 159-159
Open Access | Times Cited: 39
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years
Leora R. Feldstein, Amadea Britton, Lauren Grant, et al.
JAMA (2024) Vol. 331, Iss. 5, pp. 408-408
Open Access | Times Cited: 14
Leora R. Feldstein, Amadea Britton, Lauren Grant, et al.
JAMA (2024) Vol. 331, Iss. 5, pp. 408-408
Open Access | Times Cited: 14
Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs
Darvin Scott Smith, Maarten J. Postma, David N. Fisman, et al.
Vaccine (2025) Vol. 51, pp. 126879-126879
Closed Access | Times Cited: 1
Darvin Scott Smith, Maarten J. Postma, David N. Fisman, et al.
Vaccine (2025) Vol. 51, pp. 126879-126879
Closed Access | Times Cited: 1
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial
Ivan T. Lee, Catherine A. Cosgrove, Patrick Moore, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 9, pp. 1007-1019
Open Access | Times Cited: 37
Ivan T. Lee, Catherine A. Cosgrove, Patrick Moore, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 9, pp. 1007-1019
Open Access | Times Cited: 37
Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study
Celine Y. Tan, Calvin J. Chiew, Deanette Pang, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 12, pp. 1343-1348
Open Access | Times Cited: 34
Celine Y. Tan, Calvin J. Chiew, Deanette Pang, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 12, pp. 1343-1348
Open Access | Times Cited: 34
Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination—Evidence Synthesis and Implications for New COVID-19 Vaccines
Júlia Spinardi, Amit Srivastava
Biomedicines (2023) Vol. 11, Iss. 2, pp. 370-370
Open Access | Times Cited: 32
Júlia Spinardi, Amit Srivastava
Biomedicines (2023) Vol. 11, Iss. 2, pp. 370-370
Open Access | Times Cited: 32
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study
Alberto Mateo‐Urdiales, Chiara Sacco, Emmanouil Alexandros Fotakis, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 12, pp. 1349-1359
Open Access | Times Cited: 30
Alberto Mateo‐Urdiales, Chiara Sacco, Emmanouil Alexandros Fotakis, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 12, pp. 1349-1359
Open Access | Times Cited: 30
Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
Hagit Kopel, Văn Hùng Nguyễn, Cathérine Boileau, et al.
Vaccines (2023) Vol. 11, Iss. 11, pp. 1711-1711
Open Access | Times Cited: 22
Hagit Kopel, Văn Hùng Nguyễn, Cathérine Boileau, et al.
Vaccines (2023) Vol. 11, Iss. 11, pp. 1711-1711
Open Access | Times Cited: 22
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024
C. Kevin, Diya Surie, Adam S. Lauring, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 10
C. Kevin, Diya Surie, Adam S. Lauring, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 10
A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants
Shangchen Song, Zachary J. Madewell, Ming‐Jin Liu, et al.
Vaccine (2024) Vol. 42, Iss. 15, pp. 3389-3396
Open Access | Times Cited: 8
Shangchen Song, Zachary J. Madewell, Ming‐Jin Liu, et al.
Vaccine (2024) Vol. 42, Iss. 15, pp. 3389-3396
Open Access | Times Cited: 8
Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023
Eero Poukka, Jori Perälä, Hanna Nohynek, et al.
Eurosurveillance (2024) Vol. 29, Iss. 37
Open Access | Times Cited: 7
Eero Poukka, Jori Perälä, Hanna Nohynek, et al.
Eurosurveillance (2024) Vol. 29, Iss. 37
Open Access | Times Cited: 7
Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England
Freja Kirsebom, Katie Harman, Rachel Lunt, et al.
The Lancet Regional Health - Europe (2023) Vol. 35, pp. 100755-100755
Open Access | Times Cited: 20
Freja Kirsebom, Katie Harman, Rachel Lunt, et al.
The Lancet Regional Health - Europe (2023) Vol. 35, pp. 100755-100755
Open Access | Times Cited: 20
